Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MB-102 |
| Trade Name | |
| Synonyms | CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes|CD123 CAR-T |
| Drug Descriptions |
MB-102 is comprised of engineered T cells expressing chimeric antigen receptor consisting of CD123, CD28 fused to CD3 zeta, and a truncated EGFR (EGFRt), which may induce cytotoxic immune response against CD123-positive tumor cells (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C165435 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Decitabine + Fludarabine + MB-102 | Cyclophosphamide Decitabine Fludarabine MB-102 | 0 | 1 |
| Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab | Cyclophosphamide Fludarabine MB-102 Mesna Rituximab | 0 | 1 |
| MB-102 | MB-102 | 0 | 0 |